Cancer biotherapy - general principles, R.K. Oldham the pathogenesis of cancer metastasis - relevance to biotherapy, R. Radinsky, et al developmental therapeutics and the design of clinical trials R.K. Oldham recombinant organisms as sources of cancer biotherapeutics, K. Mehta, B.B. Aggarwal current concepts in immunology, R.K. Oldham cancer-associated immune suppression - therapeutic alterations with chemical and biological agents, R.K. Oldham nonspecific immunomodulators in oncology and haematology, G. Mathe, S. Orbach cancer vaccines - tumour epitopes and gene therapy, G.C. Fareed, L.E. Spitler chemical inducers of lymphokines, R.V. Salley, R.K. Oldham lymphokines and cytokines, W. Lewko, et al interferon therapy in cancer, R.V. Smalley, et al antibody therapy, R.O. Dillman immunotoxins, L.E. Spitler drug immunoconjugates, R.K. Oldham, K.A. Foon radiolabeled monoclonal antibodies for localization and treatment of metastatic cancer, H.B. Breitz, et al stem cell/bone marrow transplantation as biotherapy, R.K. Oldham cancer adoptive cellular immunotherapy, J.R. Yannelli growth and maturation factors in cancer, R.K. Oldham G-CSF, G. Morstyn, et al GM-CSF, A. Jakubowski clinical approaches to cancer gene therapy, K.A. Whartenby, et al cancer biotherapy - 1990s disease-related activity, R.K. Oldham, et al speculations for the 1990s, R.K. Oldham.
No takes yet. Share an insight, caveat, or question.
Robert K. Oldham (1988) studied this question.